SCHEMBL260037

SCHEMBL260037

CC1CN(Cc2c[nH]c(C=O)c2)CCO1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM2 Q14416 5/20 0.40
CNR2 P34972 3/20 0.39
CNR1 P21554 1/20 0.39
KCNH2 Q12809 1/20 0.39
DRD1 P21728 1/20 0.37
CCNC P24863 1/20 0.36
CDK8 P49336 1/20 0.36
KDM1A O60341 1/20 0.35
MCHR1 Q99705 1/20 0.35
DRD4 P21917 5/20 0.34
PDE5A O76074 1/20 0.34
PDE11A Q9HCR9 1/20 0.34
PDE10A Q9Y233 1/20 0.34
MET P08581 1/20 0.34
FGFR1 P11362 1/20 0.34
FGFR2 P21802 1/20 0.34
FGFR3 P22607 1/20 0.34
AXL P30530 1/20 0.34
PRMT5 O14744 1/20 0.34
WDR77 Q9BQA1 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL259925 0.79 HRH3 (0.45) DRD4METFGFR1FGFR2FGFR3
SCHEMBL260376 0.74 HRH3 (0.42) DRD4DRD2DRD3
SCHEMBL260714 0.74 DRD2 (0.34) KDM1ADRD4DRD2DRD3
SCHEMBL260713 0.74 DRD2 (0.34) KDM1ADRD4DRD2DRD3
SCHEMBL260817 0.74 MC4R (0.45) DRD4DRD2DRD3
SCHEMBL260511 0.74 FGFR1 (0.58) GRM2KCNH2MCHR1METFGFR1
SCHEMBL260510 0.74 FGFR1 (0.58) GRM2KCNH2MCHR1METFGFR1
SCHEMBL260905 0.73 HRH3 (0.46) DRD4DRD2DRD3
SCHEMBL13638801 0.72 GRM2 (0.46) GRM2CNR2CNR1KCNH2DRD1
SCHEMBL259653 0.72 ICAM1 (0.34) DRD4DRD2DRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101987848-B New dihydroindolone derivatives, method of preparing same and pharmaceutical compositions containing the same SERVIER LAB 2014-06-18 CN disclosed
US-8653073-B2 Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them LES LABORATOIRES SERVIER (FR) 2014-02-18 US disclosed
US-20130331380-A1 DIHYDROINDOLONE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM LES LABORATOIRES SERVIER (FR) 2013-12-12 US disclosed
US-8541412-B2 Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them LES LABORATOIRES SERVIER (FR) 2013-09-24 US disclosed
EP-2281822-B1 New dihydroindolone derivatives, method of preparing same and pharmaceutical compositions containing them SERVIER LAB (FR) 2013-01-16 EP disclosed
US-8133889-B2 Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them LES LABORATOIRES SERVIER (FR) 2012-03-13 US disclosed
US-20120046287-A1 Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them LES LABORATOIRES SERVIER (FR) 2012-02-23 US disclosed
US-20110034460-A1 Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them LES LABORATOIRES SERVIER (FR) 2011-02-10 US disclosed
EP-2281822-A1 New dihydroindolone derivatives, method of preparing same and pharmaceutical compositions containing them Les Laboratoires Servier (FR) 2011-02-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130331380-A1 DIHYDROINDOLONE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM CYP11B1, SDHA, CYP11B2 GRM2 3255/4885CNR2 716/4885CNR1 395/4885
US-20120046287-A1 Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them CYP11B1, SDHA, CYP11B2 GRM2 3255/4885CNR2 716/4885CNR1 395/4885
US-20110034460-A1 Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them CYP11B1, SDHA, CYP11B2 GRM2 3255/4885CNR2 716/4885CNR1 395/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.